Analyst Ratings for Taysha Gene Therapies (TSHA)
TSHA Rating Summary
TSHA Price Target Summary
- Highest: $19.00 (Cantor Fitzgerald)
- Lowest: $10.00 (BofA Securities)
- Average: $13.40
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$13.40 (+124.8%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 89%
Avg. $ Target:
$13.40 (+124.8%)
* Over Last 12-Mos
Rating Score: 8.9 / 10
Percentile Rank: 89%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/4/2025 | Goldman Sachs | Salveen Richter | Upgrade | Buy (Early-Stage Biotech) |
11.00 (N/A) |
4.49 (5.96) |
32.74% | Details |
| 10/21/2025 | Raymond James » Updated 3/19/2026 |
Chris Raymond | New Coverage | Strong Buy (N/A) |
13.00 (N/A) |
4.72 (5.96) |
26.27% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
